Globe News Wire
08 Dec 2025, 13:00 UTC · 40w ago
Verdict
Headline takes no side. We score IMM +1.00 across four claims — strongly bullish.
+1.00strongly bullish
More positive than 98% of ticker scores this week
What the story claims
4 claims · scored −1 bearish … +1 bullish
Immutep is eligible to receive up to USD 369.5 million in total payments from Dr. Reddy's, comprising a USD 20 million upfront payment and up to USD 349.5 million in regulatory and commercial milestones, plus double-digit royalties.
So whatThe substantial upfront cash injection strengthens Immutep's balance sheet, while the large milestone potential and double-digit royalties provide a highly material upside catalyst for the company's valuation.
More positive than 99% of claims this week
Immutep retains full development and commercialization rights to efti in key pharmaceutical markets including North America, Europe, and Japan, while out-licensing rights to the rest of the world.
Continue reading
5 related stories
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 96% of claims this week
Immutep and Dr. Reddy's entered into an exclusive licensing agreement for the development and commercialization of efti across all countries outside North America, Europe, Japan, and Greater China.
More positive than 91% of claims this week
Immutep retains global manufacturing rights to efti and will supply the product to Dr. Reddy's in the licensed markets.
More positive than 64% of claims this week
Which stocks this story touches
More positive than 98% of ticker scores this week
Secured a strategic licensing agreement including a $20 million upfront payment and potential milestones up to $349.5 million.
More positive than 74% of ticker scores this week
Expanded its oncology portfolio by gaining exclusive licensing rights to develop and commercialize Eftilagimod Alfa in multiple global markets.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
24/7 Wall Street
1d ago
[a_to_b] Immutep holds global manufacturing rights and will supply the product to Dr. Reddy's in the licensed markets.
More positive than 57% of relationship scores this week
[b_to_a] Dr. Reddy's will purchase Eftilagimod Alfa from Immutep for commercialisation in licensed markets.
—
No price for IMM right now — the quote feed didn't answer.
IMM chart →
